Systemic Lupus erythematosus-associated cardiomyopathy
Conditions
Interventions
Gold Standard:Clinical signs, hematological changes, immunological abnormalities, echocardiography, cardiac magnetic resonance imaging.
Index test:Two-dimensional speckle tracking technique and pressure-strain loop technique.
Sponsors
Second Affiliated Hospital of the People's Liberation Army Ground Force Military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: nclusion criteria for systemic lupus erythematosus: 1) SLE patients aged 18 years or older, without gender limitation, 2) SLE patients who met the diagnostic criteria of European Federation of Rheumatology/American College of Rheumatology for systemic lupus erythematosus in 2019, and 3) SLE patients with normal right heart function (RVFAC =35% , Tei index =0.43, TAPSE =17 mm) who had not developed right heart failure by routine transthoracic echocardiography. 4) complete data of clinical cases, laboratory tests and examinations. 5) willing to participate in the study and sign the informed consent. The inclusion criteria in the control group were as follows: 1) adults over 18 years of age without gender limitation, 2) normal right ventricular function (RVFAC =35% , Tei index =0.43, TAPSE =17mm) , 3) normal blood and urine routine, normal liver and renal function, normal chest x-ray and ECG.
Exclusion criteria
Exclusion criteria: Exclusion criteria for systemic lupus erythematosus:1) patients with previous congenital heart defect, cardiomyopathy, valvular heart disease heart disease, coronary heart disease, chronic obstructive pulmonary disease, pulmonary embolism and other acute and chronic heart and lung diseases, 2) patients with poor image quality who could not obtain satisfactory tricuspid or pulmonary regurgitation spectrum, 3) patients who could not cooperate with the study for any reason or who were considered unsuitable for inclusion in the study. The exclusion criteria of the control group were: 1) having a history of heart disease and other diseases affecting the heart, such as hypertension, diabetes, renal vascular disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-nuclear antibody;Anti-Sm antibody;longitudinal strain;myocardial work;right ventricular end diastolic diamete;right ventricular end systolic area;Right ventricular end-systolic area;Right ventricular area change fraction;Early diastolic peak velocity of tricuspid valve;Late diastolic peak flow velocity of tricuspid valve;Diastolic velocity of tricuspid valve annulus;Right atrial diastolic diameter;Peak systolic velocity of pulmonary artery;Rate of inferior vena cava collapse ;Sensitivity, SE;Specificity,SP;Positive predicative value, PPV; | — |
Countries
China
Contacts
Public ContactXu Yali
Second Affiliated Hospital of the People's Liberation Army Ground Force Military Medical University
Outcome results
None listed